JD.com (JD / 9618 HK) is reportedly preparing remedy tweaks to help its bid for the Cecenomy (CEC GY) deal

A remedies offer at this stage signals the transaction has reached the merger-control phase, where the binding constraint shifts from price and financing to what the acquirer is prepared to divest or concede. In cross-border retail takeovers by Chinese strategic buyers, the scrutiny has historically run on two tracks: conventional competition review, where store overlap and online-offline channel concentration drive divestiture asks, and foreign-investment screening in the target jurisdiction, where data access and supply-chain dependence have been the sticking points. Remedy tweaks of this kind are typically iterative, with an initial package refined after market testing with complainants, so the tell is whether the buyer is offering behavioural commitments or hard divestitures; regulators have tended to accept the former reluctantly in retail, and rivals have historically challenged packages they see as insufficient. The peer set reaction matters: competing bidders and domestic incumbents have on previous occasions used the remedy window to lobby or to position for carved-out assets. What follows is the sequence of the authority's response, any statement of objections or phase-two referral, and whether the parties extend longstop dates, each of which has tended to move the target's spread more than the headline concession itself.